Elevai Labs announces issuance of patent from USPTO

ELEVAI LABS announces that the United States Patent & Trademark Office, USPTO, issued US Patent No. 11,878,038, entitled “Exosome-based Skincare Product” covering the primary formulation for ELEVAI’s exosome-based skin care products. The ELEVAI exosomes used in ELEVAI Labs’ formulations are derived from specially cultured and treated umbilical mesenchymal stem cells to generate a specific profile for the applications desired. ELEVAI’s enfinity and empower(TM) formulations are both covered by the Patent. “We are pleased the USPTO has issued this critical patent, which is the first step towards building ELEVAI’s patent moat in the aesthetics market. The Company will continue to strive to invent or acquire the best and most technically advanced products, which we believe will maintain ELEVAI’s competitive edge in the physician-dispensed skincare market and beyond,” said ELEVAI co-founder and CEO, Jordan Plews, PhD.